VividWhite Glaucoma Implant (VW-51) Pivotal Study
The VividWhite Glaucoma Implant (VW-51) is a novel surgical implant designed to treat glaucoma. This study is a 12-month, 65-participant non-comparative multicentre study to assess the safety and effectiveness of the VW-51 implant.
Study details:
A prospective multicentre non-comparative pivotal clinical study where all participants undergo treatment with a novel surgical implant (VW-51) and receive 12 months of clinical follow-up. The study aim is to assess the effectiveness, safety and participant experience of the VW-51 implant for the treatment of glaucoma. The study population will involve 65 adult participants with medically or surgically refractory glaucoma.
The VW-51 implant is a leaf-shaped microfluidic device manufactured from flexible silicone, designed to be surgically implanted in the subconjunctival space, drain aqueous humor from the eye and reduce intraocular pressure to treat glaucoma.
Eligibility criteria
Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.
Inclusion criteria
- Glaucoma is diagnosed by the investigator based upon untreated intraocular pressure, disc appearance and visual field abnormalities, and where the disease type is one of: Primary open angle glaucoma (POAG); Chronic angle closure glaucoma (CACG) where the eye is pseudophakic and a laser iridotomy has previously been performed; Pigmentary open angle glaucoma; Exfoliation open angle glaucoma; Rubeotic glaucoma that is treated and regressed/quiescent; Steroid-induced glaucoma; or Juvenile open angle glaucoma (JOAG).
- There has been failure of previous treatment for glaucoma (it is 'refractory'), meeting ONE of the following requirements: i. Failure of medical treatment: inadequate IOP control on maximum tolerated medical therapy. ii. Failure of previous glaucoma surgery (not more than one operation) with trabeculectomy, Xen/PreserFlo, non-penetrating glaucoma surgery, a previously removed suprachoroidal drainage device, trabecular bypass (using iStents or Hydrus), or cilioablation.
- The mean diurnal IOP at Screening/Baseline is ≥ 20 mmHg, and ≤ 40 mmHg.
- The conjunctiva in the target quadrant is healthy, mobile and suitable for glaucoma surgery.
Exclusion criteria
- Advanced glaucomatous optic neuropathy that threatens fixation, in the opinion of the investigator.
- The glaucoma type is any of the following: Acute Angle Closure Glaucoma (AACG); Chronic Angle Closure Glaucoma where the eye is phakic; Congenital glaucoma; or Secondary glaucoma of any type not specified in the inclusion criteria, including inflammatory glaucoma, active neovascular/rubeotic glaucoma, traumatic glaucoma, Iridocorneal Endothelial (ICE) Syndrome, and silicone oil induced glaucoma.
- Previous glaucoma surgery with: a tube-and-plate glaucoma drainage device (GDD, e.g. Molteno, Baerveldt, Ahmed, Schocket); an in-situ suprachoroidal implant; or multiple previous operations for glaucoma.
- Cataract surgery or any other ocular surgery is indicated at the time of study intervention or is anticipated to be required during the study duration.
- Central corneal endothelial cell density less than specified age-related thresholds at screening.
- Intraocular silicone oil.
- Significant corneal, retinal, inflammatory or infective ophthalmic pathology (full details specified in the protocol).
Eligibility
Age eligible for study : NA
Healthy volunteers accepted : No
Gender eligible for study: ALL
Things to know
Study dates
Study start:
Primary completion:
Study completion finish:
Study type
TREATMENT
Phase
- NA
Study ID
NCT06176170
Intervention or treatment
DEVICE: VividWhite Glaucoma Implant (VW-51)
Conditions
- Glaucoma
You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.
Research sites nearby
Closest Location:
Sydney Eye Hospital
Select from list below to view details:
Sydney Eye Hospital
Sydney, New South Wales, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Cataract & Eye Surgery Centre
Doncaster East, Victoria, Australia
Cerulea Clinical Trials, Centre for Eye Research Australia
East Melbourne, Victoria, Australia
Loading map...
Who is running the clinical trial?
VividWhite Pty Ltd
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
| Participant Group/Arm | Intervention/Treatment |
|---|---|
EXPERIMENTAL: VividWhite Glaucoma Implant (VW-51)
| Device: VividWhite Glaucoma Implant (VW-51) |
What is the study measuring?
Primary Outcome
| Measure | Description | Time Frame |
|---|---|---|
| Complete success by efficacy and safety criteria | Efficacy Criteria: 1. Intraocular pressure (IOP) is less than or equal to 21 mmHg. 2. IOP is reduced by greater than or equal to 20% compared to baseline (mean diurnal). 3. Treatment with the same number or fewer classes of topical glaucoma medication than at baseline. 4. No requirement for: further glaucoma surgery indicated for efficacy (at any time during the study); or systemic/oral ocular hypotensive medication to achieve target IOP in the study eye (at any time during the study). Safety Criteria: 5. IOP is greater than or equal to 6 mmHg. 6. No adverse events of special significance in the study eye (as specified by the protocol; for example further glaucoma surgery indicated for safety). | Study completion (12 months) |
Secondary Outcome
References
Clinical Trials Gov: VividWhite Glaucoma Implant (VW-51) Pivotal StudyOther trials to consider
Loading suggested trials...
